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Summary
 
Interactions between lymphocyte surface receptors and their ligands on vascular endothelial
cells regulate the exit of lymphocytes from the circulation. Distinct subsets of mononuclear
cells bind to high endothelial venules (HEVs) in different lymphoid organs to a different extent,
but the molecular mechanisms behind this selectivity have remained poorly characterized. Here
we show that vascular adhesion protein-1 (VAP-1) mediates subtype-specific binding of CD8-
positive T cells and natural killer cells to human endothelium. VAP-1–dependent, oligosaccha-
ride-dependent peripheral lymph node (PLN) HEV adhesion under shear was independent of
L-selectin, P-selectin glycoprotein ligand 1, and 
 
a
 
4 integrins, the known lymphocyte receptors
involved in the initial recognition of endothelial cells. PLN HEV adhesion was also critically
dependent on peripheral lymph node vascular addressins (PNAds), but lymphocyte L-selectin
was absolutely required for PNAd binding. Most lymphocytes relied on both PNAd and VAP-1
in HEV binding. The overlapping function of L-selectin ligands and VAP-1 in PLN introduces
a new control point into the lymphocyte extravasation process. Finally, intravital microscopy
revealed that VAP-1 is involved in initial interactions between human lymphocytes and endo-
thelial cells in inflamed rabbit mesenterial venules in vivo. In conclusion, VAP-1 is a novel
contact-initiating ligand that discriminates between different subpopulations of mononuclear
cells and is an appealing target for selective modulation of adhesion of CD8- and CD16-posi-
tive effector cells.
 
N
 
aive lymphocytes travel continuously throughout the
body in search of antigens. Blood-borne lymphocytes
leave the circulation by binding to the endothelium of spe-
cialized postcapillary high endothelial venules (HEVs)
 
1
 
 in
lymph nodes, percolate through the tissue stroma, and
eventually return to the circulation via efferent lymphatics
(1). Virgin lymphocytes can freely traffic through both pe-
ripheral lymph nodes (PLNs) and mucosa-associated lym-
phatic tissues, which represent two functionally distinct re-
circulatory systems. It has been long known that T cells
bind and immigrate 2–5 times better to PLN than do B
cells. Conversely, B cells adhere 2–3 times more efficiently
than T cells to HEVs in mucosal lymphatic organs. More-
over, regardless of the source, CD8-positive cells bind 1.5–
2.0 times better than CD4-positive cells to PLN HEVs (2–
6). When naive lymphocytes engage their cognate antigen,
the migratory properties of the activated lymphocytes change
dramatically. They no longer randomly patrol through dif-
ferent lymphatic organs but, instead, selectively extravasate
at sites of the original antigenic insult and in related lym-
phoid tissues (7, 8).
Several classes of adhesion molecules are involved in the
extravasation process that is thought to encompass at least
three sequential but overlapping steps (7–12). The first stage
of lymphocyte extravasation is mediated by the interaction
of selectins (C type lectin-like molecules) with their oligo-
saccharide-based ligands, and it results in tethering and roll-
ing of the lymphocyte along the endothelial cell lining. Re-
versible contacts and reduction of lymphocyte speed allows
local activation of lymphocytes, which leads to triggering of
stable adhesion and diapedesis, mainly via integrin-mediated
pathways. However, no endothelial (or lymphocyte) deter-
minant has been defined so far that could explain the ob-
served in vitro and in vivo HEV-binding selectivity of dif-
ferent T and B cell subpopulations.
 
1
 
Abbreviations used in this paper:
 
 HEV, high endothelial venule; MACS,
magnetic-activated cell sorting; PLN, peripheral lymph node; PNAd, pe-
ripheral lymph node vascular addressin; PSGL-1, P-selectin glycoprotein
ligand 1; VAP, vascular adhesion protein.
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Vascular adhesion protein-1 (VAP-1) is an endothelial
molecule that supports lymphocyte binding to HEVs in
humans under nonstatic conditions (13). VAP-1 is a dimeric
170-kD sialoglycoprotein preferentially expressed on PLN
HEVs as opposed to mucosal ones. Since an anti–VAP-1
mAb inhibits 50–75% of PBL binding to PLN HEVs but
never completely abolishes the binding, we addressed the
possibility that VAP-1 would only support the HEV adhe-
sion of some leukocyte subtypes. Moreover, because VAP-1
shares many characteristics in expression, function, and struc-
ture with the prototype peripheral lymph node vascular ad-
dressin (PNAd; 14, 15), we directly compared the PLN ad-
hesion pathways mediated by VAP-1 and PNAd. Finally,
we wanted to confirm in a physiological model that VAP-1
functions under shear conditions that are relevant in vivo.
We show here that VAP-1 can bind mononuclear leu-
kocytes in a subtype-selective manner and independent of
the known lymphocyte surface receptors mediating initial
recognition of endothelial cells in PLN HEVs under non-
static conditions. We also show in an in vivo rabbit model
that blocking of VAP-1 inhibits by 30% the number of ini-
tial contacts between unselected human lymphocytes and
VAP-1 expressing mesenteric venules. Our results suggest
that endothelial binding of L-selectin negative, CD8-posi-
tive effector lymphocytes can be selectively interfered by
blocking the function of endothelial VAP-1.
 
Materials and Methods
 
Antibodies, Cells, and Tissues.
 
Function-inhibiting mAbs 1B2
against VAP-1 (13), MECA-79 against PNAd (14), WAPS12.2
against P-selectin (16), 1.2B6 against E-selectin, 1G11 against
VCAM-1 (17), Dreg-56 against L-selectin (18), HP2/1 against
 
a
 
4 integrin (19), and PL1 against P-selectin glycoprotein ligand-1
(PSGL-1; 20) have been described. A new mouse mAb, 5B11,
against human VAP-1 was produced as will be described in detail
elsewhere. FITC-conjugated mAbs against CD4, CD8, and CD14
and PE-conjugated mAbs against CD16 and CD19 were pur-
chased from Becton Dickinson (San Jose, CA). Isotype-matched
control mAbs were 3G6 against chicken T cells, 2C8 against hu-
man CD31, HB116 against human HLA ABC, TIB146 against
mouse B220 (all described in reference 21), 4D7 against v6 isoform
of human CD44 (produced in our laboratory), FITC-conjugated
3G6, and PE-conjugated L3T4 (PharMingen, San Diego, CA).
Human tonsils were from tonsillectomies and PLN were unaf-
fected nodes removed during surgical operations performed for
diagnostic purposes. Normal synovia were from bone donors, and
inflamed synovia from rheumatoid arthritis patients.
Normal PBL (either from whole blood or from buffy coats)
from healthy adults were isolated by density-gradient centrifuga-
tions over Ficoll-Hypaque. PLN-derived IL-2–activated T cell lines
were established and cultured as described (22). Tonsil lympho-
cytes were isolated by mincing the tissue and gently squeezing the
lymphocytes through a metal screen. For intravital microscopy,
tonsillar lymphocytes were labeled with a membrane-permeable
fluorescent dye Calcein–acetoxymethyl ester (Molecular Probes
Inc., Eugene, OR, 5 
 
m
 
g/10
 
7
 
 cells in RPMI for 30 min at room
temperature) and washed twice.
 
Isolation of Subfractions of Peripheral Blood Mononuclear Cells.
 
Fi-
coll-isolated blood mononuclear cells from buffy coats were used
as a starting material (1–5 
 
3
 
 10
 
8
 
 cells/subtype) for purification of
CD4- and CD8- positive T cells, CD19-positive B cells, CD16-
positive NK cells, and CD14-positive monocytes. Cells were sepa-
rated with superparamagnetic beads directly coupled with mAbs
against these different leukocyte subtype markers (CD4, CD8,
CD14, CD16, and CD19 magnetic-activated cell sorting [MACS]
beads, Miltenyi Biotec Inc., Sunnyvale, CA) according to the
protocol suggested by the manufacturer. In each case, 20 
 
m
 
l spe-
cific beads in 80 
 
m
 
l PBS containing 2% BSA were used for 10
 
7
 
cells. To isolate L-selectin–positive cells, PBL were first reacted
with mAb Leu-8 (a nonblocking anti–L-selectin antibody) and
then with mouse IgG2a
 
1
 
2b–specific microbeads. Washed cells
were subjected to MACS isolation in BS type columns, and the
bound cells were collected. For certain experiments, negatively
selected (in flow-through) cell populations depleted of CD4- or
CD8-positive PBL were isolated. L-selectin negative PBL were
isolated similarly using saturating amounts of anti–L-selectin mAb
Dreg-56 (2.5 
 
3
 
 10
 
8
 
 cells, 500 
 
m
 
g mAb) and rat anti–mouse IgG1
superparamagnetic microbeads. The specificity of the selection
was confirmed with immunofluorescence stainings using FITC-
or PE-conjugated mAbs against different epitopes as reporters.
The purity of every population used for the functional binding
assays was at least 95% and the viability of cells was 
 
.
 
95%.
 
HEV-binding Assays.
 
An in vitro frozen section assay was
used since it reproduces the in vivo homing specificity of normal
and malignant lymphoid cells (2, 23, 24) and allows studies to be
performed under conditions of low shear (rotation) with VAP-1
(and PNAd) displayed in a natural array and context on endothe-
lial cells. The human PLNs used in these studies were histopatho-
logically noninflamed and their HEVs expressed high levels of
VAP-1 and PNAd, and low levels of ICAM-1, whereas only a
negligible number of E-selectin–positive (1–2%), surface P-selec-
tin–positive (1–2%), and VCAM-1–positive (0-1%) HEVs were
encountered. When appropriate, lymphocyte binding to inflamed
tonsil and to normal and inflamed synovial samples was measured.
In vitro frozen section–binding assays were modified from a
protocol described earlier (25). In brief, 8 
 
m
 
m frozen sections
were pretreated with saturating amounts of mAbs against endo-
thelial cell adhesion molecules or with class-matched control mAbs
in a 100 
 
m
 
l volume (there is no difference in HEV adhesion of
lymphocytes when the tissue has been pretreated with a binding
or a nonbinding control; reference 26) for 30 min at 7
 
8
 
C on an
orbital shaker operating at 60 rpm. The HEV binding of lym-
phoid cells was analyzed in three types of assays. (
 
a
 
) Different sub-
populations of mononuclear cells isolated with MACS (see
above) were washed and filtered. 3 
 
3
 
 10
 
6
 
 cells in 50 
 
m
 
l RPMI
1640 medium containing 10% FCS and 10 mM Hepes were ap-
plied onto tissue sections. The assay was continued for another 30
min at 7
 
8
 
C with constant rotation. Thereafter, the nonbinding
cells were gently tilted off and the adherent cells were fixed to
sections overnight in cold PBS containing 1% glutaraldehyde.
The number of cells adhering to HEVs was counted from coded
samples under dark field microscopy. (
 
b
 
) Ficoll-isolated PBL were
labeled with FITC-conjugated anti-CD4 or anti-CD8 mAb for
15 min in RPMI 1640 medium containing 5% FCS, and washed.
Thereafter, the HEV-binding assay was performed as described
above. The number of FITC-labeled cells was scored from each
HEV under epiillumination. (
 
c
 
) When the role of different lym-
phocyte receptors as a VAP-1 counter structure was evaluated,
the cells to be tested were washed and treated with function-
blocking mAbs against L-selectin (Dreg-56), PSGL-1 (PL1), 
 
a
 
4 in-
tegrin (HP2/1), or with control mAbs. In certain experiments,
PBL were first treated with 
 
O
 
-sialoglycoprotease (2.5 
 
3
 
 10
 
7
 
 cells, 
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50 
 
m
 
l enzyme [from Cedarlane Labs. Ltd., Hornby, Canada] in
RPMI 1640, 30 min, 37
 
8
 
C), which destroys mucin-type mole-
cules including PSGL-1 (20, 27, 28). After washings, the cells
were used for the HEV-binding assays, in which the tissue sec-
tions had been pretreated with anti–VAP-1 and control mAbs as
described above. An aliquot of original and 
 
O
 
-sialoglycopro-
tease–treated PBL were used for control immunofluorescence
stainings, which revealed the expected loss of sialomucins from
the enzyme-treated cells.
All adhesion assays in 
 
a–c
 
 have been performed 2–5 times using
PLN, tonsil, and synovia from at least two different donors. At
least 120 HEVs/sample were scored. The results are expressed as
percentage of control binding (the number of cells adherent to
HEVs in the presence of an appropriate control mAb defines 100%
adherence).
 
L-selectin Transfectants and Ig Chimeras.
 
Non–HEV-binding
mouse pre–B cell L1-2 lymphoma cells stably transfected with a
full-length human L-selectin cDNA in a eukaryotic expression
vector pMRB101 have been described (15). Purified L-selectin Ig
chimera containing the extracellular part of human L-selectin
(lectin, epidermal growth factor, and two complement repeat-like
domains) fused to human IgG1 hinge, constant heavy 2 and 3 re-
gions, and a control CD4-Ig chimera have been described (29, 30).
 
Immunostainings.
 
Surface expression of VAP-1 in inflamed
rabbit mesenterial venules was studied by injecting the cross-
reacting anti–VAP-1 mAb 5B11 intravenously, killing the animal
after 15 min, making frozen sections from the rabbit organs, and
subjecting them to a second-stage peroxidase-conjugated rabbit
anti–mouse Ig in vitro. The reaction was developed by diami-
nobenzidine. Thus, a positive reaction is only seen if the mAb has
bound to its antigen exposed on the lumenal surface of the vessel
in vivo.
Cell suspensions were stained for flow cytometry analyses as
described earlier (22). 10,000 cells were analyzed using FACScan
 
Ò
 
and Lysys II software (Becton Dickinson).
 
Immunoblottings and Precipitations.
 
L-selectin and CD4 chime-
ras were loaded on protein G–beads (100 
 
m
 
g/100 
 
m
 
l beads) over-
night at 4
 
8
 
C. After washings, these beads were used to immunopre-
cipitate antigens from tonsil stromal 1% NP-40 lysates containing
2 mM CaCl
 
2
 
, 2 mM MgCl
 
2
 
, and 2 mM MnCl
 
2
 
 from which Ig
were depleted by protein G–Sepharose preincubations. The re-
sultant supernatants were used for SDS-PAGE and immunoblot-
ting using enhanced chemiluminescence. The intensity of the
bands was quantified using Microcomputer Imaging Device
(MCID; Imaging Res. Inc., Ontario, Canada).
 
Intravital Microscopy.
 
New Zealand white rabbits (2.5–2.6 kg)
were injected intraperitoneally with 2,000 IU recombinant hu-
man IL-1 in 5 ml PBS to induce inflammation and premedicated
with loperamide (Imodium, 2 mg, peroral; Janssen Pharmaceutica,
Beerse, Belgium) to reduce gut motility 3 h before the surgery.
Surgical anesthesia was induced with intramuscular injections of
midazolam (Dormicum; 2 mg/kg; Hoffmann-La Roche, Basel,
Switzerland) and fentanyl-fluanisone (Hypnorm; 0.3 ml/kg; Jans-
sen Pharmaceutica). Marginal ear vein was cannulated for contin-
uous infusion of physiological saline (6 ml/kg/h by syringe
pump, model 22; Harvard Apparatus, S. Natick, MA) and for the
maintenance of surgical anesthesia with 10% Hypnorm in aqua (3
ml/kg/h). The animals were mechanically ventilated via a tra-
cheal tube. 
Technique and procedures of intravital microscopy were
adapted from von Andrian et al. (31) and Ley et al. (32). In brief,
the mesentery was gently exteriorized, and a region near the distal
ileum and appendix was spread over a special microscope stage.
All exposed parts of the gut were covered with saline-soaked
gauze and the temperature of the preparate was adjusted to 37
 
8
 
C
by a heating lamp. The mesentery was kept moist by continuous
superfusion of thermocontrolled 37
 
8
 
C bicarbonate-buffered salt
solution (32). Appropriate venules were visualized through a
microscope (BX50WI, equipped with water immersion objectives
 
3 
 
10/0.3 and 
 
3
 
20/0.5 UMPlanFl, 3.3 mm working distance,
and a FITC/tetramethylrhodamine isothiocyanate filter block;
Olympus Corp., Lake Success, NY). After a 15-min stabilization
period, a bolus of an isotype-matched negative control mAb 4D7
was given (3.2 mg/kg) and allowed to circulate for 15 min.
Thereafter, 5–15 
 
3
 
 10
 
8
 
 Calcein-acetoxymethyl ester–labeled hu-
man tonsillar lymphocytes were filtered through a 44-
 
m
 
m silk mesh
and infused via marginal ear vein. Cells were observed with stro-
boscopic (50 s
 
2
 
1
 
 Strobex 11360; Chadwick Helmuth, Mountain
View, CA) epiillumination and low-level background light and
the data were collected with a charge-coupled device camera
(model C5405; Hamamatsu Corp., Bridgewater, NJ) using digital
video cassette recorder (DHR10000NP; Sony Corp., Montvale,
NJ). Thereafter, 3.2 mg/kg of an anti–VAP-1 mAb 5B11 was ad-
ministered and allowed to bind for 15 min. Then an equal num-
ber of fluorescently labeled tonsil lymphocytes were freshly fil-
tered and infused to the animal, and the same vessel segment was
recorded again.
The data were analyzed off-line using a slow or frame-by-
frame playback mode to assign each labeled lymphocyte either as
noninteracting (freely flowing) or interacting. Each video frame
was digitized with a custom-made frame grabber and analysis pro-
gram operating under Windows. The velocities of 
 
.
 
50 consecu-
tive lymphocytes were determined by measuring the distance
traveled between two or more successive video frames, and the
highest velocity was taken as a conservative estimate of centerline
blood velocities (V
 
CL
 
; reference 33). The mean diameter of the
vessels (d
 
vessel
 
) was measured from images in 10 different locations
along the vessel. The Newtonian wall shear rate (
 
g
 
) was counted
as described (31): 
 
g
 
 
 
5
 
 V
 
CL
 
/1.6 
 
3
 
 1/d
 
vessel
 
 
 
3
 
 8 (1/s). The shear
stress (
 
t
 
) acting on interacting lymphocytes in venules was ap-
proximated using an estimate of 0.025 Poise for the viscosity (
 
r
 
)
of blood as: 
 
t
 
 
 
5
 
 
 
g
 
 
 
3
 
 
 
r
 
 (dyn/cm
 
2
 
; reference 31).
 
Statistical Analyses.
 
The HEV-binding results are given as
mean 
 
6
 
 SEM of all experiments. The statistical significance of the
inhibitions seen in HEV-binding assays and in intravital micros-
copy were analyzed by two-tailed Student’s 
 
t
 
 test.
 
Results
 
VAP-1 Selectively Binds CD8-positive T Cells.
 
To study
the contribution of VAP-1–dependent adhesion among
different lymphocyte subpopulations, we immunomagneti-
cally purified CD4- and CD8-positive T cells and CD19-
positive B cells and analyzed their PLN HEV adhesion.
Each positively selected population was 95–100% pure when
analyzed by immunofluorescence stainings and FACS
 
Ò
 
 (data
not shown). Moreover, the presence of the minute (50-nm
diameter, 8 
 
3
 
 10
 
2
 
6
 
 volume of a lymphocyte) paramagnetic
beads on the cells did not functionally interfere with their
HEV adherence, since each purified subpopulation bound
well to PLN HEVs in the sections pretreated with the neg-
ative control mAb. Preincubation of the tissue sections
with an anti–VAP-1 mAb 1B2 displayed strikingly different
effects on the HEV binding of different lymphocyte sub- 
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populations (Fig. 1 
 
A
 
). Blocking of VAP-1 had no effect
on the capacity of CD4-positive T cells or CD19-positive
B cells to adhere to PLN HEVs. In contrast, inhibition of
VAP-1 function practically abolished all HEV binding of
CD8-positive T cells. Thus, among PBL, only CD8-posi-
tive T lymphocytes use VAP-1 in PLN HEV adhesion.
To confirm these results with an independent method,
we separately labeled freshly isolated PBL with FITC-con-
jugated mAbs against CD4 and CD8, and evaluated the
HEV binding of the labeled cells (Fig. 1 
 
B
 
). Although
CD4-positive cells always dominated in the starting popu-
lations, half of the PLN HEV–bound cells were CD8-posi-
tive when the target tissue was pretreated with an irrelevant
control antibody. When an anti–VAP-1 mAb 1B2 was used,
binding of CD8-positive cells was efficiently abrogated,
whereas this pretreatment had no effect on the HEV adhe-
sion of CD4-positive PBL. Moreover, binding of nega-
tively selected PBL depleted of CD8-positive cells to PLN
HEVs was only marginally affected (10% inhibition) by
anti–VAP-1 mAb 1B2, whereas adhesion of PBL depleted
of CD4-positive cells was inhibited 
 
z
 
70% by mAb 1B2 (Fig.
1 
 
C
 
). Thus, analyses with negatively selected PBL confirm
the results obtained with positively selected T cells.
 
VAP-1 Mediates Binding of NK Cells, but Not That of
Monocytes.
 
To analyze the behavior of other mononuclear
cells, we isolated NK cells and monocytes from blood and
analyzed their HEV adhesion. These binding assays were
done using inflamed tonsil rather than noninflamed PLNs
as the target tissue, since these two leukocyte types are known
to extravasate mainly to areas of inflammation. Anti–VAP-1
treatment markedly reduced tonsil HEV adhesion of NK
cells, but had no effect on the binding of monocytes (Fig.
2). CD16-positive cells did not adhere at all to vessels in
noninflamed nonlymphatic tissue (only two adherent CD16-
positive cells were found in 200 vessels in normal syn-
ovium), whereas these cells interacted effectively with in-
flamed vessels in inflamed synovia. Blocking of VAP-1
function abrogated 63 
 
6
 
 2% of binding of CD16-positive
cells to HEVs in inflamed synovia. Thus, only two distinct
peripheral blood leukocyte populations, CD8 T cells and
NK cells, use VAP-1 as their endothelial ligand.
 
VAP-1 Mediates L-selectin–independent PLN HEV Adhe-
sion.
 
We have shown earlier that one L-selectin–negative
IL-2–activated T cell line can adhere to tonsil HEVs in a
VAP-1–dependent manner. However, the applicability of
this finding to PBL and the question whether L-selectin
can also function as a VAP-1 receptor have not been eluci-
dated. It is also unclear whether VAP-1 mediates L-selec-
tin–independent binding also in PLNs, since HEV adhe-
sion in that organ has been thought to be solely dependent
on the function of L-selectin (15).
To address these questions, we first used PLN-derived
IL-2–dependent human immunoblasts that express no
detectable  surface L-selectin (Fig. 3 
 
A
 
, 
 
last column
 
) and are
LFA-1
 
high
 
, 
 
a
 
4
 
intermediate
 
, 
 
b
 
7
 
intermediate
 
, and CD44
 
high
 
. Intrigu-
ingly, these activated T cells bound 1.4 times better than
PBL to PLN HEVs (Fig. 3 
 
B
 
 and data not shown). As ex-
pected, no inhibition of binding was obtained by pretreating
the immunoblasts with a function-blocking anti–L-selectin
mAb Dreg-56 (Fig. 3 
 
C
 
). mAb MECA-79 pretreatment of
PLNs also had essentially no effect on adhesion, confirming
the absence of the L-selectin–PNAd pathway in this model.
In contrast, mAb 1B2 pretreatment of target tissue abol-
ished 
 
.
 
50% of immunoblast binding (Fig. 3 
 
C). Thus,
L-selectin is not a prerequisite for adherence of all types of
lymphoid cells to PLN HEVs under conditions of low
shear, since cells can directly bind to VAP-1.
VAP-1 also supported binding of normal, nonactivated,
L-selectin–negative PBL to PLN HEVs. These cells (Fig. 3 A)
bound to PLN HEVs z3 times less efficiently than unsepa-
Figure 1. VAP-1 selectively mediates HEV adhesion of CD8-positive
lymphocytes. (A) CD4-, CD8-, and CD19-positive PBL were isolated
with MACS, and their adherence to PLN HEVs pretreated with a control
or an anti–VAP-1 mAb was tested as detailed in Materials and Methods.
(B) PBL were labeled with FITC-conjugated anti-CD4 or -CD8 mAbs,
and the number of labeled cells adherent to PLN HEVs in the presence of
control and anti–VAP-1 mAbs was determined. (C) PBL were subjected
to negative selection (removal of CD8-positive cells yielding a CD8-neg-
ative population for analysis (CD82), or removal of CD4-positive cells
yielding a CD4-negative population (CD42) and the effect of anti–VAP-1
and control mAb pretreatments on HEV adhesion was determined.
Figure 2. NK, but not monocytes, use VAP-1 for endothelial binding.
CD14- and CD16-positive PBL were isolated with MACS and their bind-
ing to tonsil HEVs pretreated with a control or anti–VAP-1 mAb was
tested.593 Salmi et al.
rated PBL. Importantly, mAb 1B2 inhibited .55% of this
adhesion (Fig. 3 C). In contrast, mAb MECA-79 had no
effects. Thus, a VAP-1–dependent pathway mediates the
adherence of L-selectin negative (activated and memory)
PBL to PLN HEVs under nonstatic conditions.
Binding of an immunomagnetically separated L-selectin–
positive subpopulation of PBL to PLNs was also efficiently
blocked by mAb 1B2 pretreatment (Fig. 3 C). Therefore,
we determined whether L-selectin, although not necessary
for lymphocyte binding to VAP-1, can also function as a
receptor of VAP-1. The high level of surface expression of
human L-selectin on mouse pre–B cell lymphoma L1-2
transfectants (Fig. 4 A) was enough to confer on these
transfectants a strong ability to bind to human PLN HEVs
(Fig. 4 B). This adherence was completely inhibitable by
anti–L-selectin mAb Dreg-56 pretreatment of lymphocytes
and .70% was also abrogated by mAb MECA-79 pretreat-
ment of the endothelial cells (Fig. 4 C). In contrast, the
binding of L-selectin transfectants was completely unaf-
fected by mAb 1B2 treatment (Fig. 4 C). Hence, L-selectin
expression is sufficient to mediate binding of lymphoma
cells to PLN HEVs, but this binding is entirely indepen-
dent of VAP-1 function.
An L-selectin chimera was used to confirm that VAP-1
does not recognize L-selectin. In these experiments, tonsil
lysates were precleared with chimeric molecules containing
the extracellular domains of L-selectin or CD4 joined to
the Fc tail of IgG. As shown in Fig. 4 D, the L-selectin chi-
mera did not remove VAP-1 reactivity from lysates (lane
2), but effectively depleted most mAb MECA-79 reactivity
(lane 6). Image analyses revealed 78, 56, and 62% reduction
of the 170-, 105-, and 50-kD forms of PNAd, respectively,
when compared to precipitations with a control CD4 chi-
mera. Hence, all three detectable species of MECA-79 an-
Figure 3. VAP-1 mediates binding of both L-selectin–positive and –negative lymphocytes to PLN HEV. (A) Expression of L-selectin on different
lymphocyte populations. Total PBL, immunomagnetically separated L-selectin–positive and –negative subpopulations of PBL, and IL-2–activated T cells
were stained for L-selectin expression and analyzed using FACScanÒ. (B) L-selectin–negative T cells specifically recognize PLN HEVs. Five immuno-
blasts (black round cells, two pointed out by arrows) binding to a HEV (lilac basement membrane outlined by a dashed line) are shown in the micrograph. Bar, 20
mm. (C) Binding of these different lymphocytes to PLN HEVs after pretreatments with the indicated mAbs was analyzed.594 Vascular Adhesion Protein 1 Selectively Binds CD8-positive Lymphocytes
tigens bound to L-selectin, whereas L-selectin did not in-
teract with VAP-1.
VAP-1 Binds to a Novel Contact-initiating Receptor on Lym-
phocytes. In addition to L-selectin, a4 integrins and PSGL-1
can mediate tethering and rolling of lymphocytes on vascu-
lar endothelium or isolated endothelial ligands (28, 33–36).
To address whether a4 integrins can function as lympho-
cyte ligands of VAP-1, we analyzed the role of a4 integrin
in PLN HEV adhesion of L-selectin–negative PBL (Fig. 5).
A function-inhibiting anti-a4 mAb, HP2/1, which detects
both a4b1 and a4b7 heterodimers, had no effect on ad-
herence of these cells to HEVs under rotatory conditions.
Moreover, mAb 1B2 still efficiently inhibited PLN HEV
adhesion of a4-blocked PBL, indicating that functional a4
is not needed to support VAP-1–dependent binding. VAP-1
function was independent of the lymphocyte PSGL-1 as
well. When PBL were pretreated with a function-blocking
anti–PSGL-1 mAb PL1, z10% inhibition in lymphocyte
binding to tonsil HEV was seen. When the anti–PSGL-1
mAb–treated PBL were added to anti–VAP-1 mAb–treated
Figure 4. VAP-1 does not recognize L-selectin. (A) Expression of human L-selectin
on mouse L1-2 L-selectin transfectants. (B) L1-2 L-selectin transfectants (dark blue spots)
efficiently bind to human PLN HEVs (seven different-sized HEV, one outlined by a
dashed line, can be seen as light blue structures). (C) L1-2 L-selectin transfectant binding
to HEV in human PLNs is independent of VAP-1. Transfectants were pretreated with
Dreg-56 and PLN tissue with 1B2 and/or MECA-79, and the HEV adhesion was deter-
mined. (D) L-selectin chimera binds PNAd, but not VAP-1. The Ig-chimeras were used
to deplete tonsil lysate and the nonprecipitated molecules were analyzed using immuno-
blotting and the mAbs indicated.595 Salmi et al.
tonsil sections, 10% additive inhibitory effect on the adhe-
sion was seen when compared to the effect of the anti–
VAP-1 mAb alone. To assess the role of other sialomucins
as potential counterreceptors for VAP-1, we treated lym-
phocytes with the sialomucin-degrading enzyme O-sia-
loglycoprotease, and then analyzed the VAP-1 dependence
of their tonsil HEV binding. This treatment had a marginal
effect on PBL adhesion to HEV, but the binding of O-sia-
loglycoprotease–treated cells was still efficiently blocked by
mAb 1B2 pretreatment of the target tissue indicating that an
O-sialoglycoprotease–sensitive molecule is not at least the
principal lymphocyte ligand of VAP-1. Thus, none of the
currently known lymphocyte adhesion molecules (L-selec-
tin, a4 integrins, or PSGL-1) mediating rolling on endo-
thelial cells are receptors for VAP-1.
VAP-1 and PNAd Both Mediate PLN HEV Adhesion of
PBL. Next we wanted to see whether VAP-1 and PNAd
represent two distinct adhesion routes to PLN HEVs.
Binding of normal PBL, which contain 50–80% L-selectin
positive cells, to PLN HEVs was reduced by z75% with sepa-
rate anti-PNAd, anti–L-selectin, and anti–VAP-1 treatments
in these assays (Fig. 6). In contrast, E-selectin, P-selectin,
and VCAM-1 played no role in PBL binding to normal
PLN. When the function of both VAP-1 and PNAd was
blocked, we observed z10% more inhibition of HEV
binding when compared to sections pretreated with mAb
MECA-79 only. This additive inhibition was seen in every
experiment performed, but it failed to reach statistical sig-
nificance (P 5 0.07 when comparing MECA-79 pretreat-
ment to combined MECA-79 and 1B2 pretreatment).
These data indicate that most PBL use both VAP-1 and
PNAd to bind to PLN HEVs, but also reveal that a small PBL
subpopulation may rely exclusively on VAP-1. L-selectin
was also important for PLN HEV adhesion of CD8-posi-
tive PBL (Fig. 7). In support of additional inhibition of to-
tal PBL binding to PLN HEVs seen by combined blocking
of PNAd and VAP-1, combined blocking of both L-selec-
tin and VAP-1 also produced more marked inhibition in
PLN HEV adhesion of CD8-positive PBL than blocking of
either adhesion molecule separately.
VAP-1 Mediates Initial Contacts Between Lymphocytes and
Inflamed Endothelium In Vivo. To confirm that VAP-1
could mediate initial interactions between PBL and endo-
thelial lining under physiologically relevant conditions, we
used intravital microscopy. Since mAb 1B2 does not cross-
react with laboratory rodents, we screened a new panel of
anti–human VAP-1 mAbs against different animal species
and found that one mAb, 5B11, cross-reacts with rabbit. mAb
5B11 is specific against VAP-1 since it stains the same
structures in human tissues as the prototype mAb 1B2, it
reacts in immunoblotting with a 170-kD molecule that is
absent from a lysate after preclearing with 1B2-coupled
beads, and it reacts with VAP-1 transfectants (data not
shown). mAb 5B11 inhibits human PBL binding to human
tonsil HEVs in Stamper-Woodruff assay at least as effi-
ciently as 1B2. Importantly, mAb 5B11 recognizes in rab-
bits an antigen with similar tissue and cell distribution to hu-
man VAP-1 (Fig. 8 a), and mAb 5B11 abrogated 75% of
Figure 5. VAP-1 binds to a
novel contact initiating lympho-
cyte counterreceptor. PBL were
treated with the indicated mAbs
(HP2/1 and PL1) against lym-
phocyte adhesion receptors or
with  O-sialoglycoprotease (O-sgp),
and their binding to the target
tissue treated with anti–VAP-1
or control mAbs was evaluated.
Binding of PBL treated with
anti–a4 integrin mAb was tested
to PLN HEVs, whereas binding
of PBL pretreated with anti–
PSGL-1 mAb and O-sgp was
evaluated using tonsil as a target
tissue.
Figure 6. Most PBL use both
PNAd and VAP-1 in PLN HEV
binding. PBL were treated with
anti–L-selectin mAb and PLNs
with mAbs against different en-
dothelial adhesion molecules
alone or in combination, and the
HEV adherence was determined.596 Vascular Adhesion Protein 1 Selectively Binds CD8-positive Lymphocytes
binding of rabbit mesenterial lymph node lymphocytes to
rabbit mesenterial lymph node HEVs indicating conserved
function of VAP-1 between humans and rabbits. This mAb
also detects rabbit VAP-1 on the surface of inflamed mesente-
rial venules 4 h after IL-1–induced peritonitis (Fig. 8 c).
In rabbits treated with an isotype-matched control mAb
4D7, which reacts to neither human lymphocytes nor rab-
bit endothelium, fluorescently labeled human tonsillar lym-
phocytes interacted with inflamed endothelium as observed
by intravital microscopy. The estimated Newtonian wall
shear stress was 4.0–7.8 dyn/cm2 in the venules (diameter
21–50 mm) analyzed. The majority of labeled cells was de-
tected in the freely flowing fraction, but 14–26% of cells
interacted with the endothelial cells. Most interacting cells
typically displayed transient tethering to the endothelium,
and few showed a rolling type movement along the endo-
thelium (Fig. 8, d–o). Cell labeling did not adversely affect
the rolling capacity of human lymphocytes in rabbits, since
the same cells showed typical rolling in Peyer’s patch HEVs
(which, however, were VAP-1 surface negative). Notably,
anti–VAP-1 mAb 5B11 pretreatment diminished the num-
ber of labeled cells interacting with VAP-1–positive me-
senterial endothelial cells by 33 6 5% (mean 6 SEM of
three independent assays with different rabbits, P 5 0.0242
when compared to control mAb treatment periods; Fig. 8
p). The effect of anti–VAP-1 pretreatment was quite re-
markable since only z10% of tonsillar cells were CD8 pos-
itive. Thus, VAP-1 does support initial contacts between
human lymphocytes and vessel wall under physiologically
relevant shear conditions.
Discussion
Our results show that VAP-1 mediates leukocyte sub-
type-specific recognition of HEVs under nonstatic conditions
in humans, and hence introduces a new way of generation
of the selectivity of leukocyte–endothelial interactions in
the multistep adhesion cascade. VAP-1 is able to mediate
PLN HEV adhesion of both L-selectin–positive, and im-
portantly, L-selectin–negative lymphoid cells. Moreover,
VAP-1 supports initial contacts (tethering and rolling) be-
tween lymphocytes and inflamed endothelium under phys-
iologically relevant shear conditions in an animal model.
Thus, VAP-1 extends the role of carbohydrate-dependent
lymphocyte–endothelial cell interaction beyond the known
selectins.
VAP-1 mediates HEV binding of lymphocytes, but not
that of monocytes. Even more strikingly, only CD8-posi-
tive T cells and CD16-positive NK cells recognized VAP-1,
whereas CD4-positive T cells and B cells adhered indepen-
dently of VAP-1. Thus, VAP-1–dependent binding divides
T cells dicotomically into two populations. Therefore, VAP-1
is the first defined endothelial adhesion molecule, which
can explain the better binding of CD8- than that of CD4-
positive T cells to PLN HEVs (5). Very recently it has been
shown that Th1, but not Th2, CD4 cells bind to P- and
E-selectin in mice (37). Together, these findings indicate
that endothelial adhesion molecules may display greater se-
lectivity toward defined lymphocyte subpopulations than
previously anticipated.
VAP-1 mediates oligosaccharide-dependent adhesion to
endothelial cells under nonstatic shear conditions (26), im-
plying that it is involved relatively early in the adhesion
cascade. Using intravital microscopy, we showed here that
VAP-1 plays a role in the initial recognition of at least in-
flamed endothelium by human lymphocytes. Anti–VAP-1
mAb pretreatment diminished the number of lymphocytes
tethering and rolling on the vessel wall by z30%. This is a
notable reduction since only z10% of tonsil lymphocytes
were CD8 positive and thus able to interact with VAP-1,
and since all other adhesion pathways were left intact.
These data suggest that VAP-1 functions quite early in the
adhesion cascade, but we cannot rule out the possibility
that it would play a role as an accessory molecule, e.g., as a
part of a larger receptor complex or as a signaling molecule.
On lymphocytes there are three known homing receptors,
L-selectin, PSGL-1, and a4 integrins, mediating the initial
tethering and rolling, and all of them recognize multiple
endothelial and other ligands (7, 8). Therefore, it was of
importance to see that none of these molecules served as
the lymphocyte counterreceptor of VAP-1, although we can-
not formally rule out the possibility that CD8- and CD16-
positive cells would possess an L-selectin with unique post-
translational modifications that would render it capable of
interacting with VAP-1. VAP-1–dependent binding is sialic
acid dependent and VAP-1 contains both a2,3 and a2,6
sialic acid linkages (26). Thus, another lectin type molecule
preferentially expressed on CD8-positive cells and NK cells
would be an appealing candidate as a VAP-1 counterreceptor.
The ability of VAP-1 to bind L-selectin–negative cells to
PLNs deserves special emphasis. L-selectin is readily shed from
the lymphocyte surface, and hence recently activated lym-
phocytes are L-selectin negative (18, 38, 39) and a large
subpopulation of circulating CD45RO1RA2 memory cells
Figure 7. CD8-positive PBL
use both L-selectin and VAP-1
to adhere to PLN HEVs. Posi-
tively selected CD8-positive cells
(CD81) were treated with anti–
L-selectin and control mAb,
PLN tissue section was pre-
treated with anti–VAP-1 and
control mAb, and the HEV
binding was determined.597 Salmi et al.
also lack L-selectin (40). It has remained enigmatic how
these effector cell types can home to PLNs. We showed
here that both totally L-selectin–negative activated immu-
noblasts and L-selectin–negative PBL can use VAP-1 in
PLN HEV adhesion. These observations provide a molec-
ular basis for those studies that have reported that L-selec-
tin–negative cells nevertheless do bind to PLN HEVs. For
example, we have shown earlier that L-selectin–negative
cell lines derived from human tissues bind to PLN HEVs by
unknown mechanisms (22). Moreover, L-selectin–negative
T cell lines injected intravenously into mice have been re-
ported to home into PLNs (41), and in antibody inhibition
experiments, blockade of L-selectin only causes a 75% re-
duction of PLN homing in vivo (42). The putative mouse
homologue of VAP-1 might well explain the residual lym-
phocyte trafficking seen in these animal models.
Our results appear to contradict those obtained in L-selectin
knockout mice, in which 95–99% abrogation of HEV adhe-
sion of mutant lymphocytes to PLN HEVs in Stamper-
Woodruff  assay has been reported, and in which no homing
of lymphocytes into PLNs was detected (43, 44). We be-
lieve that there may be species-specific differences in the be-
havior of L-selectin–negative cells, and that in human
L-selectin–independent PLN HEVs recognition may play a
more prominent role. However, the other examples referred
to above indicate that PLN HEVs homing of L-selectin–
Figure 8. VAP-1 mediates initial interactions between human lympho-
cytes and inflamed vascular endothelium in vivo. (a) An anti–human
VAP-1 mAb 5B11 recognizes VAP-1 in HEVs in frozen sections of rabbit
mesenterial lymph node. (b) Negative control staining with mAb 4D7.
An HEV is pointed out by an arrow. (c) Rabbit VAP-1 is expressed on
the luminal surface of inflamed mesenterial vessel. After intravenous in-
jection of mAb 5B11, the in vivo–bound mAb was immunohistochemi-
cally detected in the mesenterial section with a second-stage peroxidase-
conjugated anti–mouse Ig. (d–o) Intravital microscopy was used to study
the effect of a control mAb 4D7 and an anti–VAP-1 mAb 5B11 on bind-
ing of fluorescently labeled human tonsillar lymphocytes with inflamed
mesenterial vessels in rabbits as detailed in Materials and Methods. (d) A
micrograph of one segment of the vessel under study. L, lumen of the
vessel; T, connective tissue of the mesenterium; white triangles, the walls of
the vessel; white arrows, rolling rabbit granulocytes. (e–i) A tethering lym-
phocyte. The same segment as in d viewed under stroboscopic epiillumi-
nation after injecting fluorescently labeled human cells. A cell (1) docks to the vessel wall in e, moves less than 5 mm/s during the first 800 ms (e–f), speeds
up in g, and detaches in h–i. A freely flowing cell (2; velocity 1,110 mm/s) is also seen. Arrows mark a reference point at the vessel wall. (j–o) A rolling
lymphocyte. In another segment of a venule, a lymphocyte (3) that rolls along the bottom of the vessel for .2.5 s is seen (average velocity z24 mm/s).
Blood flow (open arrowhead) is from left to right in d–i and from top to bottom in j–o. White lines, vessel walls. Time codes in the upper right corners in-
dicate the time elapsed (in ms) from the first frame of the series. Bar, 10 mm. (p) Anti–VAP-1 mAb 5B11 reduces interactions between human lympho-
cytes and rabbit vessel wall when analyzed by intravital microscopy in three independent experiments. Number of control interactions was arbitrarily set
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negative cells can also be detected in mice. The reasons for
this discrepancy remain elusive, but may include strain dif-
ferences, other aberrations in congenitally L-selectin–defi-
cient animals (e.g., lack of maturational signals for the naive
CD8-positive PBL deprived of lymph node microenviron-
ment; see also reference 45), or subtle technical differences
in the in vitro adhesion assay (Arbones et al. measured
binding of mouse splenocytes from knockout mice to rat
PLN HEVs after additional washes, counterstaining, and
mounting; reference 43). It is also worth noting that many
groups that have reported L-selectin to be absolutely neces-
sary for PLN HEV binding use the original Stamper-
Woodruff assay (23) in which the target tissue has been
fixed with 3% glutaraldehyde before performing the bind-
ing assay. This treatment renders VAP-1, and possibly also
some other adhesion molecules, completely nonfunctional,
and hence excludes the possibility of detecting L-selectin–
negative lymphocyte binding via VAP-1.
Our data from the in vitro functional studies show that at
least two distinct pathways are operative in mediating lym-
phocyte–PLN HEV interaction under shear in humans: (a)
L-selectin–PNAd and (b) non–L-selectin–VAP-1. At least
in mice, binding of lymphocyte to PNAd in PLNs can also
occur in vivo via a platelet bridge in which lymphocyte
PSGL-1 binds to (presumably) P-selectin on activated plate-
lets, and then other P-selectin molecules of the platelet in-
teract with PNAd (46). CD44 is also involved in PLN
HEV adhesion in humans (47), although in mouse models,
CD44 may not be involved in PLN homing (48). In our
experimental setup, P- and E-selectin, or interaction of a4
integrins with VCAM-1 and mucosal addressin cell adhe-
sion molecule 1 do not play any role on PLN HEV adhe-
sion. Most PLN type HEVs synthesize both VAP-1 and
PNAd, but exclusive expression of VAP-1 or PNAd in
certain HEVs offers a possibility to fine tune tissue-selective
endothelial cell binding of lymphocytes by virtue of L-selec-
tin expression status of the lymphocyte. Since combined
VAP-1 and PNAd blockade was only minimally synergistic,
the most likely possibility is that, for most lymphocytes, both
molecules are involved and that they mediate sequential but
overlapping events. For many L-selectin–positive lympho-
cytes, interaction through both PNAd and VAP-1 may oc-
cur, in parallel or sequentially. Involvement of VAP-1 and
PNAd might be analogous, for example, to the roles of
L-selectin and a4b7 integrin in lymphocyte homing to
mucosa-associated Peyer’s patch HEVs. In this site, L-selectin
initiates the contact more avidly than a4b7; both mole-
cules participate in rolling before lymphocyte activation
and a4b7-mediated slowing of rolling appears essential for
subsequent activation-dependent arrest involving b2 inte-
grins (33, 35). Thus, if our in vitro observations reflect the
situation in PLNs in vivo, L-selectin and PNAd might ini-
tiate contact more efficiently than VAP-1, but VAP-1 may
be required for subsequent events before stable arrest.
L-selectin–negative cells, on the other hand, can omit the
PNAd binding and directly rely on VAP-1 in PLN HEV
adhesion. Finally, results from our functional assays indicate
a significant subpopulation of lymphoid cells (probably in-
cluding many CD4-positive cells) adheres to PLN HEVs
under nonstatic conditions by novel non–VAP-1–, non-
PNAd–, and non–L-selectin–dependent mechanism(s).
VAP-1 selectively mediates PLN HEV adhesion of CD8-
positive lymphocytes, and it can bind either L-selectin–
negative or –positive cells. VAP-1 is the first endothelial
adhesion molecule that mediates leukocyte–HEV binding
in a subtype specific manner. Identification of VAP-1 as a
new contact initiating ligand provides a unique molecular
pathway for regulating the specificity and diversity of the
initial steps of lymphocyte–endothelial cell interactions.
Moreover, manipulation of VAP-1 opens new avenues for
selective control of the trafficking of CD8-positive lym-
phocytes and NK cells. Selective blocking of the migration
of these effector cells by VAP-1 antagonists should ablate
much of the untoward inflammatory damage seen at differ-
ent clinical conditions, and yet leave the other arms of the
immune system intact.
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